Agios Pharmaceuticals, Inc.
AGIO
$35.00
-$2.22-5.97%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 12.46M | 8.73M | 10.73M | 8.96M | 8.62M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.46M | 8.73M | 10.73M | 8.96M | 8.62M |
| Cost of Revenue | 93.64M | 73.83M | 84.07M | 73.24M | 78.90M |
| Gross Profit | -81.19M | -65.10M | -73.34M | -64.27M | -70.28M |
| SG&A Expenses | 45.87M | 41.53M | 51.70M | 38.54M | 35.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 139.51M | 115.36M | 135.77M | 111.78M | 114.43M |
| Operating Income | -127.06M | -106.63M | -125.04M | -102.81M | -105.82M |
| Income Before Tax | -112.02M | -89.29M | -105.40M | 1.00B | -96.12M |
| Income Tax Expenses | -- | -- | -8.88M | 53.12M | -- |
| Earnings from Continuing Operations | -112.02M | -89.29M | -96.52M | 947.92M | -96.12M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -112.02M | -89.29M | -96.52M | 947.92M | -96.12M |
| EBIT | -127.06M | -106.63M | -125.04M | -102.81M | -105.82M |
| EBITDA | -125.80M | -105.35M | -123.67M | -101.47M | -104.22M |
| EPS Basic | -1.93 | -1.55 | -1.69 | 16.65 | -1.69 |
| Normalized Basic EPS | -1.21 | -0.97 | -1.15 | -0.97 | -1.06 |
| EPS Diluted | -1.93 | -1.55 | -1.69 | 16.22 | -1.69 |
| Normalized Diluted EPS | -1.21 | -0.97 | -1.15 | -0.94 | -1.06 |
| Average Basic Shares Outstanding | 57.93M | 57.46M | 57.10M | 56.94M | 56.80M |
| Average Diluted Shares Outstanding | 57.93M | 57.46M | 57.10M | 58.43M | 56.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |